BioSpace News Archive

This collaboration combines Click Therapeutics’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in clinical development of treatments for neuropsychiatric diseases, furthering Boehringer Ingelheim’s commitment to exploring digital innovations to benefit patients with unmet medical needs

-- Brings expertise and leadership in scaling engineering and digital tools throughout her career as a tech entrepreneur --

Oragenics, Inc. (NYSE American: OGEN) , a biopharmaceutical company dedicated to the development and commercialization of a vaccine candidate to combat the novel coronavirus pandemic (commonly referred to as COVID-19) today announces that Alan Joslyn, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference (the “Conference”). The Conference is to

Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in a live Q&A at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Friday, September 18, 2020 at 8:00 a.m. ET and host investor meetings. To access

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the presentation of five scientific posters highlighting data regarding BELBUCA at the 14 th Annual PAINWeek 2020 National Conference on Pain Management taking place virtually September 11-13, 2020. Poster Presentations: A Phase I Placebo-Controlled Trial Compar

With much of the COVID-19 response to date focusing on human-to-human transmission of the virus, the importance of environmental monitoring remains largely unaddressed.

Presentation today during Joint ACTRIMS-ECTRIMS Meeting at MSVirtual2020 Data indicate a continued positive safety profile and the potential to improve MS visual and functional endpoints [11-September-2020] SALT LAKE CITY , Sept. 11, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation

Poster Presentation Shares New Data on the Symptoms and Impacts of Fatigue Using a New Disease-Specific Scale Global Patient Survey Reveals Approximately Two-Thirds of Multiple Sclerosis Patients Experience Fatigue on a Daily Basis

Patients Who Achieved SDI at Any Timepoint Maintained it at All Future Timepoints; Higher Proportion of Patients Showing SDI with Increasing Dose Patients Achieving SDI Also Demonstrated Trend Toward Improvement in Fatigue and Physical Function at 12 Months First Available Data from Open Label Expansion Show Patients with SDI at 12 Months, Maintained SDI at Later Time Points Conference Call and Webcast Today, September 11, 2020 at 8:30

Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”) is delighted to announce that initial sales of its GeneType for Breast Cancer Risk Assessment have now commenced in the United States via an online health platform, elicity by InTeleLabs, an independent telehealth and personalised medicine company.